Calcitonin News
Bone Medical further positive results from oral osteoporosis drug trial
Bone Medical Limited (ASX:BNE) has obtained important positive data on blood levels of peptide from testing its oral parathyroid hormone (PTH) CaPTHymone™ osteoporosis product.
Correlation of Procalcitonin and Cytokine Expression with Dehiscence of Wartime Extremity Wounds
Background: Despite technological advances in the treatment of severe extremity trauma, the timing of wound closure remains the subjective clinical decision of the treating surgeon. Traditional serum markers are poor predictors...
Unigene to Present at the 20th Annual Roth Capital Partners Growth Stock Conference
Unigene Laboratories, Inc.’s President and CEO, Dr. Warren Levy, will speak at the ROTH Capital Partners Growth Stock Conference on Thursday, February 21, 2008. Dr. Levy will present information on Unigene’s products and...
Unigene Initiates Phase I/II Clinical Study for Oral Calcitonin
Unigene Laboratories, Inc. (OTCBB: UGNE) has initiated a Phase I/II clinical study in the U.S. with its proprietary formulation of oral calcitonin for the treatment of osteoporosis. Twenty-four healthy postmenopausal women have...
Bone Medical Positive New Data From Oral Osteoporosis Drug Trial
Bone Medical Limited has been advised of new positive data from its second clinical trial conducted to test CaPTHymone™ (Bone's oral parathyroid hormone (PTH)) product for treatment of osteoporosis.